NanoGroup S.A. and BIOTECHNA S.A., a Krakow-based company specializing in innovative anticancer therapies based on nanotechnology and RNA, have signed a letter of intent (LOI). The document formalizes the start of negotiations for the potential acquisition by NanoGroup S.A. of a stake in BIOTECHNA.

The signed document paves the way for the start of negotiations, conducting a due diligence process and working out the terms of a potential transaction.

BIOTECHNA focuses on innovative cancer therapies, including the development of therapeutic RNA and nanoparticle drug carriers. The company is engaged in advanced research projects, carried out with the support of public funds and cooperation with leading scientific units in Poland.

NanoGroup is developing projects based on respiratory gas transport systems and innovative polysaccharide nanoparticles for cancer therapies.

The Companies will report on subsequent activities in accordance with applicable regulations.

*It should be emphasized that the letter of intent does not create a legally binding commitment to carry out the transaction.

link to ESPI https://biznes.pap.pl/wiadomosci/firmy/nanogroup-sa-92025-zawarcie-listu-intencyjnego-z-biotechna-sa

ABOUT BIOTECHNA S.A. – an innovative biotechnology company focused on developing the next generation of anti-cancer therapies. The company specializes in advanced drug nanocarrier technologies (lipid and polymer formulations) and therapies using nucleic acids (RNA).